Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options (Q38077127)

28 August 2017

1 reference

title

Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options (English)

1 reference

chronic renal insufficiency

28 August 2017

1 reference

1 reference

Eva E Vink

1

1 reference

28 August 2017

Rosa L de Jager

series ordinal

2

1 reference

28 August 2017

Peter J Blankestijn

series ordinal

3

1 reference

28 August 2017

1 April 2013

1 reference

Current Hypertension Reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

2

1 reference

28 August 2017

95-101

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-013-0328-5

28 August 2017

0 references

cites work

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic nervous system overactivity and its role in the development of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

A limited renal injury may cause a permanent form of neurogenic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal afferent denervation prevents hypertension in rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic hyperactivity in chronic renal failure: a wake-up call

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic overactivity in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic nerve activity in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Sympathetic nerve activity is inappropriately increased in chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Autonomic renal denervation ameliorates experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Nitric oxide, oxidative stress, and progression of chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Moxonidine treatment of hypertensive patients with advanced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Beta blockers in the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal sympathetic-nerve ablation for uncontrolled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0328-5

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure

21 January 2018

1 reference

12 December 2020

Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy

1 reference

12 December 2020

Renal noradrenaline spillover correlates with muscle sympathetic activity in humans

1 reference

12 December 2020

Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients

1 reference

12 December 2020

A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two beta-blocking drugs, nipradilol and propranolol

1 reference

12 December 2020

Baroreflex control of sympathetic nerve activity in essential and secondary hypertension

1 reference

12 December 2020

Atorvastatin reduces sympathetic activity in patients with chronic kidney disease

1 reference

12 December 2020

Altered norepinephrine turnover in the brain of rats with chronic renal failure.

1 reference

12 December 2020

Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions

1 reference

12 December 2020

Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series

1 reference

12 December 2020

Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats

1 reference

12 December 2020

Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension.

1 reference

12 December 2020

Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure

1 reference

12 December 2020

Sympathetic outflow to muscles during treatment of hypertension with metoprolol

1 reference

12 December 2020

Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient

1 reference

12 December 2020

Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade

1 reference

12 December 2020

Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment

1 reference

12 December 2020

Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog.

1 reference

12 December 2020

Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension

1 reference

12 December 2020

Early sympathetic activation in the initial clinical stages of chronic renal failure

1 reference

12 December 2020

Renal structure and hypertension in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

10.1007/S11906-013-0328-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference